HUTCHMED (HCM) said Thursday it earned a $20 million milestone payment from Takeda (TAK) triggered by reaching over $200 million in sales of metastatic colorectal cancer treatment fruquintinib.
Takeda, who holds exclusive global rights to the drug outside of mainland China, Hong Kong and Macau, generated $203 million in net sales of fruquintinib in nine months ended September 2024, the comany said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。